Core Insights - Biotricity Inc. and B-Secur are enhancing their joint cardiac monitoring platform to support ECG data from consumer wearables, transforming the consumer wearables market [1][2][3] - The device-neutral platform launched in early 2025 allows seamless integration of data from various smart devices into Biotricity's cloud-based medical workflow [2][4] - This advancement positions Biotricity and B-Secur as leaders in digital cardiovascular innovation, addressing the growing demand for preventive cardiovascular solutions [3][5] Company Overview - Biotricity aims to make high-quality cardiac care accessible through its collaboration with B-Secur, introducing clinical-grade heart monitoring to consumer wearables [4][7] - B-Secur specializes in advanced biosensing technology, providing medical-grade ECG data for faster diagnosis and management of health conditions [6] - Both companies are focused on bridging the gap between consumer devices and clinical care, enhancing preventive and personal care solutions [4][7] Market Context - Cardiovascular disease accounts for 1 in 3 deaths globally and is projected to triple costs to $1.8 trillion by 2050, highlighting the urgent need for scalable preventive technologies [5] - The integration of consumer wearables into clinical pathways is expected to improve long-term health outcomes while reducing healthcare costs [5]

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Semler Scientific, Inc. (NASDAQ: SMLR) securities between March 10, 2021 and April 15, 2025. Semler Scientific describes itself as a company that develops and markets technology products and services that assist its customers in evaluating and treating chronic diseases. For more information, submit a form, email attorney Aaron Dum ...

Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara’s President and Chief ...

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical dataMENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that its TearCare System, has been in ...

YOKNEAM, Israel, Sept. 2, 2025 /PRNewswire/ --  InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present in-person at the Baird 2025 Global Healthcare Conference in New York on Sept. 10, 2025.The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 8:30 am Eastern Time on Wednesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold o ...

Core Insights - ONWARD Medical N.V. reported strong demand for its ARC-EX System in the US and achieved FDA IDE approval for the Empower BP study, indicating positive commercial and regulatory momentum [2][6]. Commercial Traction - The company successfully sold 30 ARC-EX Systems to US clinics in the first half of 2025, meeting its sales targets and demonstrating strong demand [3][7]. - Access to US government procurement platforms was secured, allowing Veterans Affairs and other government buyers to purchase the ARC-EX System [4]. Regulatory Milestones - ONWARD submitted a 510(k) application to the FDA for home use of the ARC-EX System and filed for CE Mark certification in the EU [5][7]. - The FDA approved an investigational device exemption (IDE) for the ARC-IM System, enabling the start of the Empower BP study [6][7]. Science & Technology Leadership - The Pathfinder2 study showed that sustained access to ARC-EX Therapy leads to continued functional improvements after one year of treatment [9]. - The first human implant of the investigational ARC-IM Lumbar Lead was successfully completed, aimed at restoring mobility [11]. Financial Highlights - The company reported EUR 1.2 million in revenue for the first half of 2025, with an operating loss of EUR 20.0 million [15][17]. - The cash position at the end of June 2025 was EUR 40.9 million, up from EUR 32.1 million at the end of 2024 [17]. Outlook - Continued strong demand for the ARC-EX System and positive user feedback suggest the company is on track to meet its sales targets for Q3 2025 [18]. - The company anticipates first patient enrollment in the Empower BP study before the end of the year and plans additional implants of its ARC-IM and ARC-BCI systems [19].

Core Insights - Bio-Rad Laboratories, Inc. (BIO) is positioned for growth due to strong demand for its QX600 Droplet Digital PCR (ddPCR) platform and robust performance in Clinical Diagnostics [1][4] - The company has experienced a decline in share price by 11.7% over the past year, contrasting with the industry's growth of 3.4% and the S&P 500's rise of 15.7% [2] - Bio-Rad's market capitalization stands at $8.06 billion, with earnings surpassing estimates in three of the last four quarters, averaging a surprise of 34.5% [2] Growth Drivers - The QX600 ddPCR platform is expanding, with new assay enhancements and the acquisition of Stilla Technologies aimed at entering new molecular testing markets [4] - The introduction of the IH-500 NEXT System in 2023 has strengthened Bio-Rad's position in Clinical Diagnostics, maintaining strong demand for quality control and immunology products [5] - The company expects mid-single-digit revenue growth for its ddPCR portfolio by 2025 following the Stilla acquisition [4] Financial Health - Bio-Rad reported cash and cash equivalents of $1.37 billion and only $1 million in short-term debt at the end of Q2 2025, indicating strong solvency [6] - Total debt remained stable at $1.20 billion, which is lower than the cash and cash equivalents [6] Challenges - The company faces challenges from weak end markets, particularly in the biopharma sector, with a 1.7% year-over-year revenue decline in its core Life Science Group [9] - Competitive pressure is significant, with large corporations and startups competing aggressively, limiting Bio-Rad's pricing strategies [9] - The proposed reductions in federal funding for institutions within Bio-Rad's customer base have led to cautious capital allocation among customers [9] Earnings Estimates - The Zacks Consensus Estimate for Bio-Rad's 2025 earnings per share (EPS) has increased by 5% to $9.69, while revenue estimates are projected at $2.58 billion, reflecting a modest 0.6% increase from the previous year [10]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, the company faced a risk of a civil lawsuit, leading to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the settlement announcement, Semler Scientific's stock price fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4].

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences: Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ETMorgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET A live webcast of the presentations will be availabl ...

Core Insights - Carlsmed, Inc. reported a revenue of $12.1 million for Q2 2025, marking a 99% year-over-year growth from $6.1 million in Q2 2024 [1][3] - The company expects full-year revenue for 2025 to be between $45.5 million and $47.5 million, representing a growth of 67% to 75% compared to 2024 [4] Financial Performance - Gross profit for Q2 2025 was $8.9 million, up from $4.6 million in Q2 2024, with a gross margin of 73.4% compared to 75.0% in the prior year [3] - Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, driven by higher sales and marketing expenses [3] - The net loss for Q2 2025 was $6.8 million, slightly higher than the $6.3 million loss in Q2 2024 [3] Operational Highlights - The company successfully completed its first personalized cervical spine surgery using the AI-enabled aprevo technology platform in July 2025 [2][3] - The aprevo cervical procedures received CMS New Technology Add-On Payment (NTAP) reimbursement effective October 1, 2025 [3] Market Positioning - Carlsmed's growth is attributed to the adoption of its AI-enabled aprevo technology platform, which is recognized for delivering better patient outcomes compared to traditional devices [2] - The company aims to establish itself as the new standard of care in spine fusion surgery as it enters the second half of 2025 [2]